IDH2 and leukemia: IDH-mutant gliomas are the most recent IDH-mutant cancers to demonstrate clinical benefit from mIDH inhibitor treatment (following IDH-mutant leukemia and IDH-mutant cholangiocarcinoma), and these results reflect the culmination of more than a decade of basic, translational, and clinical research efforts.